TriangleATRA (NCT06536413)
ATRA trial for Relapsed/Refractory Multiple Myeloma (NCT06536413). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for multiple myeloma in adults whose disease did not respond to a proteasome inhibitor drug such as carfilzomib.
The idea: add all-trans retinoic acid, or ATRA, to carfilzomib and dexamethasone. Three ATRA dose levels are tested. Carfilzomib is given by vein. Patients must have had at least three earlier lines of treatment.
This phase 1 and 2 study looks at safety, tolerability and the recommended dose, and plans 42 patients. At Houston Methodist Neal Cancer Center in Texas, Sai Ravi Pingali leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.